As of Feb 12
| +0.11 / +1.48%|
The 8 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 22.00, with a high estimate of 27.00 and a low estimate of 7.00. The median estimate represents a +191.78% increase from the last price of 7.54.
The current consensus among 9 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.